NCT07334275

Detection of Minimal Residual Disease Post-prostatectomy

Pilot Study for the Detection of Minimal Residual Disease Post-prostatectomy and Early Disease Recurrence in Circulating Tumor DNA to Guide Future Adjuvant Therapy in High-risk Prostate Cancer Patients (MiRaDE)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: Radboud University Medical Center · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The clinical objective for this pilot study is to determine whether minimal residual disease (MRD) detection in high-risk prostate cancer, utilizing a custom-made prostate-specific circulating tumor DNA (ctDNA) panel, may lead to more optimal prediction of disease recurrence following radical prostatectomy.

Conditions

• Prostate Cancer

Timeline

• Start date: 2025-09-16
• Primary completion: 2027-07-01
• Completion: 2028-01-01
• First posted: 2026-01-12
• Last updated: 2026-01-12

Locations

1 site across 1 country: Netherlands